Safety and efficacy of inhaled IBIO123 for severe COVID-19, new results.

October 6, 2023

Immune Biosolutions is pleased to share the most recent findings from our second Phase 1/2 clinical trial (NCT05303376). This study focused on evaluating the safety and efficacy of repeated doses of IBIO123 in treating severe COVID-19 cases among recently hospitalized patients.

Article available in preprint:

Similar Posts